Sentynl Therapeutics, in partnership with Eiger BioPharmaceuticals, has finalized the acquisition of Eiger’s Zokinvy® (lonafarnib) program. This landmark move signifies a significant step forward in addressing rare and orphan diseases, particularly Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), and Processing-Deficient Progeroid Laminopathies (PDPL).

Zokinvy® stands out as the first and only treatment endorsed by the U.S. Food and Drug Administration (FDA) to target both the cause and symptoms of Progeria, a condition that accelerates mortality in young patients. Its approval in 2020 in the United States, followed by approvals in the European Union, Great Britain in 2022, and Japan in January 2024, underscores its global significance in combating these ultra-rare, fatal, genetic premature aging diseases.

Speaking on this acquisition, Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd, expressed optimism about expanding their portfolio to include medicines for rare and orphan diseases. He emphasized the pivotal role Zokinvy® plays in supporting patients to lead healthier and more fulfilling lives, highlighting its meaningful impact on young patients and their families.

Matt Heck, President & CEO of Sentynl, echoed these sentiments, underscoring their commitment to providing global access to Zokinvy® and serving patients and families affected by Progeria. He expressed gratitude to Eiger and The Progeria Research Foundation for their efforts in developing and ensuring availability of this life-changing treatment.

David Apelian, MD, PhD, MBA, CEO of Eiger, conveyed satisfaction in completing the agreement with Sentynl, emphasizing their shared commitment to supporting patients with life-threatening rare conditions. Audrey Gordon, President and Executive Director of The Progeria Research Foundation (PRF), lauded the impact of Zokinvy® in extending the lives of children with Progeria and expressed excitement about joining forces with Sentynl to further advance research and treatment for this syndrome.

The acquisition follows Eiger's filing for chapter 11 bankruptcy in April 2024, with Sentynl designated as the winning bidder in the court-supervised sale process. Under the terms of the acquisition, Sentynl has acquired global rights to Zokinvy® and will oversee its manufacture and commercialization.

For inquiries regarding continued access to Zokinvy®, individuals can reach out to the Sentynl Cares support team. This acquisition marks a significant milestone in the ongoing efforts to address rare diseases and underscores the collaborative efforts of stakeholders to improve the lives of patients worldwide.